Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Other Accumulated Expenses (2016 - 2026)

Cumberland Pharmaceuticals' Other Accumulated Expenses history spans 16 years, with the latest figure at $12.6 million for Q4 2025.

  • On a quarterly basis, Other Accumulated Expenses rose 3.14% to $12.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $12.6 million, a 3.14% increase, with the full-year FY2025 number at $12.6 million, up 3.14% from a year prior.
  • Other Accumulated Expenses hit $12.6 million in Q4 2025 for Cumberland Pharmaceuticals, up from $10.1 million in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for CPIX hit a ceiling of $17.6 million in Q4 2022 and a floor of $7.6 million in Q3 2021.
  • Historically, Other Accumulated Expenses has averaged $12.3 million across 5 years, with a median of $12.5 million in 2022.
  • Biggest five-year swings in Other Accumulated Expenses: dropped 24.67% in 2021 and later surged 102.9% in 2022.
  • Tracing CPIX's Other Accumulated Expenses over 5 years: stood at $8.7 million in 2021, then surged by 102.9% to $17.6 million in 2022, then dropped by 22.69% to $13.6 million in 2023, then decreased by 9.9% to $12.3 million in 2024, then increased by 3.14% to $12.6 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for CPIX at $12.6 million in Q4 2025, $10.1 million in Q3 2025, and $10.1 million in Q2 2025.